Effect of Lymphadenectomy on Survival in Early-Stage Type II Endometrial Carcinoma and Carcinosarcoma

Purpose. We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma. Methods. We evaluated 135 patients with clinically early-stage (Stage I-II) type II endomet...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology 2020, Vol.2020 (2020), p.1-6
Main Authors: Salihoglu, Yavuz, Topuz, Samet, Giray, Burak, Sahin Ersoy, Gulcin, Sozen, Hamdullah, Vatansever, Dogan, Iyibozkurt, A. Cem
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Carboplatin
Carcinoma
Chemotherapy
Dissection
Endometrial cancer
Histology
Lymphatic system
Medical prognosis
Metastasis
Patients
Radiation therapy
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose. We aimed to investigate whether systematic pelvic and paraaortic lymph node dissection delivers any survival advantage in a subgroup of patients with type II endometrial carcinoma and carcinosarcoma. Methods. We evaluated 135 patients with clinically early-stage (Stage I-II) type II endometrial carcinoma and carcinosarcoma who underwent systematic pelvic and paraaortic lymph node dissection or who did not undergo any lymph node dissection. Results. Overall survival (OS) and recurrence-free survivals (RFS) were significantly longer in the systematic lymph node dissection group (hazard ratio 0.28, 95% CI 0.13–0.62 p=0.002 for OS and hazard ratio 0.31, 95% CI 0.14–0.69 p=0.004 for RFS). Multivariate analysis showed that lymph node dissection, age, lymph node metastasis, and adjuvant therapy were independent prognostic variables of OS and RFS. Conclusions. Systematic pelvic and paraaortic lymph node dissection independently and significantly prolongs the survival of patients with early-stage type II endometrial carcinoma and carcinosarcoma.
ISSN:1687-8450
1687-8450
1687-8469
DOI:10.1155/2020/1295613